The Portrait of Cancer Immunotherapy: Tumor Microenvironment, Biomarkers and Immune Resistance—Volume II
Deadline for manuscript submissions: closed (20 September 2023) | Viewed by 4154
Interests: cancer immunology; cancer immunotherapy; biomarkers; precision oncology; immune resistance; cancer vaccines; immune escape; immune checkpoint inhibitors
Special Issues, Collections and Topics in MDPI journals
This Special Issue is the second edition of a previous issue on the topic of “The Portrait of Cancer Immunotherapy: Tumor Microenvironment, Biomarkers and Immune Resistance”.
The exploitation of immune lymphocytes’ capacity to specifically recognize and destroy autologous tumor cells has revolutionized the treatment paradigm across a variety of human cancers. Cancer immunotherapy has made several major breakthroughs in the past few years, and immune checkpoint blockade (ICB) has become the cutting-edge therapy for many cancer types with persisting clinical responses. Nevertheless, enthusiasm about the use of ICB in cancer immunotherapy has been significantly mitigated by the fact that only 20%–30% of patients respond to this type of treatment. This underscores the importance to more precisely investigate the complex interactions between tumors and the various elements and factors within the tumor microenvironment (TME) that comprise or modulate the antitumor immune response. This will lead to a better understanding of the immune context of the TME and its role in generating antitumor immunity or immune resistance, thus providing the mechanistic impact for novel combination therapies. On this basis, high-throughput analyses of tumor specimens, peripheral blood, and multiplex imaging followed by computational analyses are imperative for the identification of novel biomarkers or biomarker signatures to optimize immunotherapies.
In this Special Issue, experts in the field of cancer immunotherapy will review the role of the TME in regulating clinical responses during immunotherapies by promoting antitumor immunity or immune resistance, and will discuss recent therapeutic modalities that modulate the TME to reinforce preexisting or therapy-induced antitumor immunity. The predictive role of biomarkers in the peripheral blood for immunotherapy efficacy in patients with various types of cancer will also be reviewed.
Moreover, this Special Issue will include new research articles related to research into a broad range of immunotherapy treatments including cellular therapies, vaccines, and ICB; the identification of new predictive biomarkers and therapeutic targets in the TME and peripheral blood; novel therapeutic approaches; and the use of immune modulators to overcome immune resistance. Results from multicenter clinical studies discovering novel prognostic and/or predictive signatures will also be covered.
Dr. Constantin N. Baxevanis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.